Mitochondrial dynamics in type 2 diabetes: Pathophysiological implications

Susana Rovira-Llopis, Celia Bañuls, Noelia Diaz-Morales, Antonio Hernandez-Mijares, Milagros Rocha, Victor M. Victor

Abstract

Mitochondria play a key role in maintaining cellular metabolic homeostasis. These organelles have a high plasticity and are involved in dynamic processes such as mitochondrial fusion and fission, mitophagy and mitochondrial biogenesis. Type 2 diabetes is characterised by mitochondrial dysfunction, high production of reactive oxygen species (ROS) and low levels of ATP. Mitochondrial fusion is modulated by different proteins, including mitofusin-1 (MFN1), mitofusin-2 (MFN2) and optic atrophy (OPA-1), while fission is controlled by mitochondrial fission 1 (FIS1), dynamin-related protein 1 (DRP1) and mitochondrial fission factor (MFF). PARKIN and (PTEN)-induced putative kinase 1 (PINK1) participate in the process of mitophagy, for which mitochondrial fission is necessary. In this review, we discuss the molecular pathways of mitochondrial dynamics, their impairment under type 2 diabetes, and pharmaceutical approaches for targeting mitochondrial dynamics, such as mitochondrial division inhibitor-1 (mdivi-1), dynasore, P110 and 15-oxospiramilactone. Furthermore, we discuss the pathophysiological implications of impaired mitochondrial dynamics, especially in type 2 diabetes.

1. Introduction

Hyperglycemia and type 2 diabetes are directly related to oxidative stress. In fact, a high production of reactive oxygen species (ROS) and a subsequent change in redox state and cellular homeostasis has been described in type 2 diabetes. Mitochondria are one of the main sources of ROS and the major site of ATP production. When levels of glucose are high, mitochondria enhance ROS production and induce oxidative stress and tissue damage as a result [1].

Mitochondrial impairment can also contribute to the development of age-dependent insulin resistance [2]. Mitochondria biogenesis contributes to modulate the energy balance, and an enhanced production of ROS by the electron transport chain under hyperglycemic conditions is thought to exacerbate pathological pathways, leading to diabetic microvascular (nephropathy, retinopathy and neuropathy) and macrovascular (stroke, myocardial ischemia) complications [3].

All of the aforementioned characteristics suggest that mitochondria play a key role in insulin resistance in general and in type 2 diabetes in particular. Therefore, mitochondrial quality must be well controlled. Different mechanisms have been used by mitochondria to control their homeostasis; for example, mitochondrial fusion and fission are key to the repair of mitochondrial damaged components, allowing the exchange of material between damaged and non-damaged mitochondria via the fusion process, or segregation of damaged components via the fission process [4,5]. Other mechanisms for maintaining mitochondrial homeostasis are the proteolytic system, the proteasome, and the formation of mitochondria-derived vesicles under oxidative stress conditions which can be degraded by lysosomes.

Abbreviations: AMPK, AMP-activated protein kinase; ATP6, activating transcription factor 6; BNP3, BCL2/adenovirus E1B 19 kDa interacting protein 3; CHOP, C/EBP homologous protein; DRP1, dynamin-related protein 1; FIS1, fission protein 1; GPR78, 78 kDa glucose-regulated protein; IMM, inner mitochondrial membrane; LC3, 1A/1B-light chain 3; mdivi-1, mitochondrial division inhibitor-1; MFF, mitochondrial fission factor; MFN1, mitofusin 1; MFN2, mitofusin 2; MiD49, mitochondrial dynamics proteins of 49; MiD51, mitochondrial dynamics proteins of 51 kDa; mtDNA, mitochondrial DNA; mTOR, mammalian target of rapamycin; NF-kB, nuclear factor kappa B; Nox 4, NADPH oxidase-4; OMM, outer mitochondrial membrane; OPAL, optic atrophy 1; p38 MAPK, p38 mitogen-activated protein kinase; PINK1, (PTEN)-induced putative kinase 1; ROS, reactive oxygen species; S3, 15-Oxopiramilactone; SIK1/3, siruin 1/3; SOD, superoxide dismutase; XBP1, spliced X-box binding protein 1; TGF-β1, transforming growth factor-β1; TRX2, thioredoxin 2; TXNIP, thioredoxin interacting protein; p62/SQSTM1, ubiquitin and sequestosome-1; UCP-1, uncoupling protein-1; Sod, mitochondrial membrane potential

*Correspondence to: FISABIO, University Hospital Doctor Peset, Avda Gaspar Aguilar 90, 46017 Valencia, Spain.
E-mail address: victor.victor@uv.es (V.M. Victor).

These authors have contributed equally

http://dx.doi.org/10.1016/j.redox.2017.01.013
Received 25 November 2016; Received in revised form 5 January 2017; Accepted 13 January 2017
Available online 16 January 2017
Damaged mitochondria can also form autophagosomes to trigger their degradation into the lysosomes via mitophagy [6–8]. All of these aspects suggest that mitochondria may play a critical role in the pathophysiology of diabetes. It is important to take into account that mitochondria are not static; in fact they are highly dynamic and constantly changing in shape, size and location within the cells, which confers them high plasticity.

In type 2 diabetic patients, high levels of glucose can induce glucose oxidation, thereby generating pyruvate and NADH. Furthermore, ROS are released from mitochondrial complex I and III. In these conditions different antioxidant systems are triggered, such as manganese superoxide dismutase (SOD) or uncoupling protein-1 (UCP-1), to prevent ROS production and inhibit the formation of advanced glycation end products or nuclear factor kappa beta (NF-κB) activation [9], thus impeding a chronic proinflammatory state.

In this context, it is important to highlight the concept of mitochondrial homerins in type 2 diabetes [10], which involves a reduction of ROS production and ATP synthesis in different tissues in response to high levels of glucose or excess of nutrient intake, constituting a compensatory response to overnutrition. This effect can activate sirtuin 1/3 (SIRT1/3), AMP-activated protein kinase (AMPK) and PGC-1α, therefore restoring mitochondrial function and increasing insulin sensitivity in β-cells, liver and muscle, which, in turn, prevents vascular complications [10].

In summary, mitochondrial function depends on their quality control, and an essential characteristic of this quality control is the high level of plasticity in their dynamic structures, which allows them to constantly change by fusion and fission processes [11]. Mitochondrial dysfunction, on the other hand, can play a critical role in the development of type 2 diabetes and insulin resistance-related diseases.

In the present review, mitochondrial fusion and fission dynamics, their alteration in type 2 diabetes, and the targeting of mitochondrial dynamics will be discussed, in addition to the pathophysiological implications of these aspects.

2. Mitochondrial fusion and fission dynamics

During physiological conditions mitochondria undergo morphological changes in order to adapt to cellular energetic demands. These changes can occur through the continuous cycles of mitochondrial fusion and fission that allow an adequate distribution of mitochondria within the cells. Therefore, mitochondria are not static organelles; they change their shape and location depending on physiological stimuli. Mitochondrial fusion produces small individual mitochondria, whereas large interconnected networks of mitochondria are generated through fusion. The morphology of mitochondria varies widely across different cell types; hepatocytes, for example, have small spherical or oval mitochondria, whereas fibroblast mitochondria are long filaments [12,13].

Several dynamin-related GTPases constitute the core machinery of mitochondrial fusion/fission processes. Mitofusin (MFN) 1 and 2 are responsible for outer mitochondrial membrane (OMM) fusion. MFN1 proteins can interact intermitochondrially, tethering two opposing mitochondria through their HR2 domains [14]. As for MFN1, MFN2 proteins interact among themselves, but they also heterooligomerize with MFN1 to promote mitochondrial fusion (Fig. 1) [15]. MFN2 also participates in the physical interaction between endoplasmic reticulum and the mitochondria, which is essential for Ca2+ signalling [16].

Whereas mitofusins mediate fusion of the OMM, fusion of the inner mitochondrial membrane (IMM) is orchestrated by optic atrophy 1 (OPA1) protein, which is also involved in maintenance of the mitochondrial cristae structure [17]. On the other hand, fission proteins include dynamin-related protein 1 (DRP1) and fission protein 1 (FIS1). DRP1 molecules assemble into a ring-like structure to constrict mitochondrial membranes in a GTP-dependent manner, while FIS1 is anchored to the OMM and seems to participate in the recruitment of DRP1 through its cytosolic domain [18]. Other OMM proteins that mediate the recruitment of DRP1 are mitochondrial fission factor (MFF) and the mitochondrial dynamic proteins of 49 (MiD49) and 51 kDa (MiD51), the latter two being sufficient to mediate fission in the absence of FIS1 and MFF [19] (Fig. 1).

Fusion and fission processes are essential for the maintenance of important cellular functions such as mitochondrial respiratory activity, mitochondrial DNA (mtDNA) distribution, apoptosis, cell survival or calcium signalling. ATP production is modulated by mitochondrial networks generated by fusion and this pathway is controlled by transmitting the membrane potential from areas of high O2 availability to those with low availability, thus allowing the dissipation of energy [12]. Whereas this pro-fusion state is typical in situations of increased energy efficiency due to starvation or acute stress, the opposite occurs when cells are subjected to a large nutrient supply such as in obesity or type 2 diabetes. Exposure to an excess nutrient environment promotes mitochondrial fission and decreases mitochondrial fusion, which is related to uncoupled respiration [20]. In addition, mitochondrial fusion is crucial for the removal of damaged mitochondria by mitophagy [21], as discussed later.

Therefore, the regulation of mitochondrial dynamics is a complex process involving different dynamin-related GTPases that maintain a balance between mitochondrial fusion and fission. Any alteration of this balance can involve oxidative stress, mitochondrial dysfunction and metabolic alterations, eventually promoting the development of mitochondria-related diseases, such as insulin resistance and type 2 diabetes. In this sense, several studies suggest that genetic ablation of fusion proteins alters glucose homeostasis and promotes insulin resistance and obesity in mice [22,23]. In addition, recent evidence shows that genetic ablation of Drp1 or Mfn1 in the liver protects mice against HFD-induced obesity and insulin resistance [24,25]. These findings highlight the important role of mitochondrial dynamics in the regulation of glucose metabolism and insulin signalling, and, in turn, in the development of obesity and type 2 diabetes.

2.1. Mitochondrial dynamics and mitophagy

The maintenance of a healthy mitochondrial population is essential for cell survival. Cells employ the mechanism of autophagy to remove defective organelles and recycle their essential components through their encapsulation by a double-membrane structure known as the autophagosome. In the case of mitochondria, this mechanism is known as mitophagy [26]. The importance of a proper regulation of mitophagy lies in the fact that when a damaged mitochondrion fuses with a healthy one, the result is not a larger healthy organelle, but rather a larger damaged mitochondrion, which could expand the damage by releasing high amounts of ROS [27]. In this sense, mitochondrial fission plays a central role, since mitophagy is preceded by mitochondrial division, which generates individual mitochondrial fragments of manageable size for encapsulation [8] (Fig. 2). To achieve this profusion state, the fusion proteins MFN1 and MFN2 are degraded by the ubiquitin proteasome system during the induction of mitophagy, whereas OPA1 is degraded by the IMM zinc metalloprotease OMA1 and AAA proteases [28]. The main orchestrators of the process of mitophagy are (PTEN)-induced putative kinase 1 (PINK1), the ubiquitin ligase PARKIN, ubiquitin and sequestosome-1 (p62/SQSTM1). PINK1 and PARKIN are both indispensable for mitophagy, since loss of any of these proteins results in failure of selective mitochondrial clearance [29]. Upon malfunctioning of a mitochondrion, it suffers a depolarization, which interrupts normal proteolytic processing of PINK1, leading to PINK1 accumulation in the mitochondrion and phosphorylation of its targets, which include ubiquitine and PARKIN. Afterwards, PARKIN mediates the ubiquitination of the OMM, tagging it for p62 binding, which is linked to the autophagosomal microtubule-associated protein 1 A/1B-light chain 3 (LC3), leading eventually to the
targeting of the mitochondrion for mitophagy [30].

Alterations in the expression of some of the aforementioned proteins alter mitochondrial dynamics and mitophagic recycling, and can have an impact on the development of certain diseases. Examples of this are mutations in parkin, which cause early-onset familial Parkinson’s disease through defects in mitophagy, and the loss of function of pink1, which is involved in a recessive familial form of Parkinson’s disease, by causing an elongation of mitochondrial filaments. Both types of genetic mutation lead to neuronal alterations related to the development of parkinsonism [31,32].

3. Type 2 diabetes and mitochondrial dynamics

Mitochondrial dynamics is crucial in type 2 diabetes and its vascular complications. In fact, mitochondria are master regulators of insulin secretion, and mtDNA mutations have been related to the development of type 2 diabetes. In fact, a novel mutation m.8561 C > G in MT-ATP6/8 (subunits of mitochondrial ATP synthase) has recently been reported to cause diabetes mellitus and hypergonadotropic hypogonadism [33]. In the study in question, the authors demonstrated that this mutation leads biochemically to impaired assembly and decreased ATP production of mitochondrial ATP synthase. Furthermore, it is important to take into account that mitochondria

Fig. 1. Regulation of mitochondrial fusion and fission. Mitochondrial fusion is mediated by homo- and heterotypic interactions between mitofusin (MFN) 1 and 2 at the outer mitochondrial membrane and optic atrophy protein 1 (OPA1) at the inner mitochondrial membrane. Receptor-mediated recruitment by dynamin-related protein-1 (DRP1) from the cytosol to the outer mitochondrial membrane by fusion protein 1 (FIS1), mitochondrial fission factor (MFF), and mitochondrial dynamics proteins of 49 and 51 kDa (MiD49/51) to sites of division marked by endoplasmic reticulum drives mitochondrial fission. DRP-1, dynamin-related protein-1; FIS 1, fusion protein 1; IMM, inner mitochondrial membrane; OMM, outer mitochondrial membrane; MFN 1/2, mitofusins 1 and 2; OPA1, optical atrophy 1; MFF, mitochondrial fission factor; MiD49, mitochondrial dynamics protein of 49 kDa; MiD51, mitochondrial dynamics protein of 51 kDa; ER, endoplasmic reticulum.

Fig. 2. Schematic representation of mitochondrial fission and mitophagy. Mitophagy is preceded by mitochondrial division, which generates individual mitochondrial fragments of feasible size for encapsulation. Upon malfunctioning of a mitochondrion, it suffers a depolarization, which interrupts normal proteolytic processing of PINK1, leading to PINK1 accumulation in the mitochondrion and phosphorylation of its targets, which include ubiquitine and PARKIN. Afterwards, PARKIN mediates the ubiquitination of the OMM, tagging it for p62 binding, which is linked to the autophagosomal LC3 protein, leading eventually to the targeting of the mitochondrion for mitophagy. DRP-1, dynamin-related protein-1; FIS1, fission 1 protein 1; PINK1, (PTEN)-induced putative kinase 1; LC3, microtubule-associated protein 1 A/1B-light chain 3; p62, ubiquitin-binding protein 62.
are one of the main sources of ROS and also mediate cellular apoptosis and cell death.

β-cells synthesize insulin, and this secretion is modulated mainly by glucose levels. In relationship to this, an enhanced level of glucose induces oxidative phosphorylation in β-cells, increasing the ATP/ADP ratio and inhibiting K⁺ channels that can depolarize the plasma membrane and lead to enhanced Ca²⁺ levels inside the cells. This effect triggers the secretion of insulin into the blood stream in order to maintain adequate levels of glucose [34,35]. Therefore, insulin secretion is modulated by the bioenergetic state of mitochondria.

Insulin resistance is a common characteristic of type 2 diabetes and mitochondrial dysfunction has been associated with it [36–39]. An inhibition of mitochondrial function and an increase in lipid peroxidation have been described in skeletal muscle of insulin-resistant patients [40]. Furthermore, a downregulation of genes involved in mitochondrial biogenesis and oxidative phosphorylation has been observed in type 2 diabetes [41]. Recently, it has been demonstrated that obese patients presented a global expression downregulation of mitochondrial oxidative pathways with concomitant downregulation of mtDNA, mtDNA-dependent translation system and protein levels of the oxidative phosphorylation machinery, when compared with lean co-twins. In fact, a downshifting of fatty acid oxidation, ketone body production and breakdown, and tricarboxylic acid cycle was observed and inversely correlated with insulin resistance, adiposity and inflammatory cytokines [42].

There is evidence that exercise, resveratrol, mitochondrial-targeted antioxidants and caloric restriction improve insulin sensitivity and mitochondrial function in type 2 diabetes [43–47] (Fig. 3). For example, metformin and resveratrol have demonstrated beneficial effects by protecting mitochondrial integrity through the inhibition of DRP1 activity, and preventing NLRP3 inflammasome activation by suppressing endoplasmic reticulum stress, thereby protecting cell function under hyperglycemic conditions [48].

Mitochondrial-targeted antioxidants such as SS-31 have also been shown to exert beneficial effects by modulating mitochondrial membrane potential (ΔΨm) and ATP alterations and inhibiting the expression of NADPH oxidase-4 (Nox 4) and TGF-β1 (TGF-β1) and the activation of p38 mitogen-activated protein kinase (p38 MAPK) and NADPH oxidase activity in mesangial cells under hyperglycemia. SS-31 treatment also upregulated the expression of thioredoxin 2 (TRX2), demonstrating beneficial effects in the treatment of diabetic nephropathy [49].

Exercise can also improve mitochondrial function and insulin sensitivity, as demonstrated in numerous studies. In this sense, we would like to highlight a recently published review [50] that summarises the effect of a planned self-directed exercise intervention in individuals with type 2 diabetes; namely an improvement in HbA1c, cardiorespiratory fitness, physical characteristics and functional measures.

Finally, caloric restriction has also been demonstrated to exert beneficial effects in type 2 diabetic patients. For example, the study by Sathananthan et al. showed that six weeks of caloric restriction decreased fasting glucose and endogenous glucose production, with subsequent improvements in β cell function in type 2 diabetic patients [51]. An additional 6 weeks of caloric restriction maintained the improvement in glucose metabolism.

Oxidative stress and type 2 diabetes are related to changes in the ΔΨm of β-cells. This alteration in β-cells could be closely related to altered mitochondrial dynamics, leading to impaired glucose-stimulated insulin secretion, as suggested by previous studies [52,53]. During type 2 diabetes, fusion and fission processes are continuously altered in β-cells, and it has been demonstrated that hyperglycemia and enhanced levels of palmitate decrease fusion and inhibit mitochondrial oxygen consumption [54,55]. Furthermore, one recent study has

Fig. 3. Interaction between mitochondrial dynamics, oxidative stress and mitochondrial function in type 2 diabetes. Mitochondria are one of the main sources of ROS/RNS and also mediate cellular apoptosis and cell death. Oxidative stress and type 2 diabetes are related to changes in the ΔΨm that could be related to altered mitochondrial dynamics. There is evidence that exercise, drugs, mitochondrial-targeted antioxidants and caloric restriction improve insulin sensitivity and mitochondrial function in type 2 diabetes. In contrast, mtDNA mutations, enhanced calcium levels, poor glycemic control or lipid peroxidation enhance oxidative stress and can be related to the development of type 2 diabetes.
demonstrated that PINK1 alleviates palmitate-induced insulin resistance in hepatic cells by suppressing ROS-mediated MAPK pathways [56].

Type 2 diabetes is related to a reduced expression of MFN2, which may be linked to an impairment of mitochondrial function in skeletal muscle [57]. Our group has recently demonstrated that mitochondrial fusion was reduced and fission increased in leukocytes from type 2 diabetic patients, while both features were accentuated in patients with poor glycemic control [36]. In addition, we demonstrated that leukocyte rolling flux increased in parallel to HbA1c levels, and that induction of leukocyte-endothelial interactions in diabetic patients was related to reduced mitochondrial fusion and higher mitochondrial fission. Our results suggest that mitochondrial dynamics is influenced by glycemic control in the leukocytes of diabetic patients, in which there is a decreased mitochondrial fusion and elevated fission related to enhanced leukocyte-endothelial interactions. We hypothesise that poor glycemic control during type 2 diabetes alters mitochondrial dynamics and eventually promotes leukocyte-endothelial interactions and the onset of cardiovascular diseases [36].

Other studies in insulin resistant patients have demonstrated that exercise promotes an improvement in fat oxidation and insulin sensitivity, as well as a decrease in DRP1 and an increase of MFN1 and MFN2 expression [58]. In addition, it has recently been shown that exercise prevents the decline in the MFN2/DRP1 ratio in the db/db mice hearts, and that exercise attenuates ΔΨm decline and cytochrome c leakage. The authors is question concluded that moderate intensity exercise produces significant cardiovascular benefits by improving mitochondrial function through restoration of mitochondrial biogenesis regulators (MFN2 and DRP1), Cex43 networks and mitochondrial ΔΨm and prevention of excessive mitochondrial fission [59].

Furthermore, in recent years it has been demonstrated that mitochondria-associated endoplasmic reticulum membranes reorganize under insulin resistance conditions and decrease O2 consumption, thereby enhancing oxidative stress [60]. In our laboratory, we have demonstrated that 78 kDa glucose-regulated protein (GRP78) levels thereby enhancing oxidative stress [60]. In our laboratory, we have demonstrated that 78 kDa glucose-regulated protein (GRP78) levels were higher in type 2 diabetic patients than control subjects; whereas patients with good glycemic control (HbA1c < 7%) displayed higher levels of spliced X-box binding protein 1 (sXBP1), and those with HbA1c > 7% exhibited preferentially enhanced levels of C/EBP homologous protein (CHOP) and activating transcription factor 6 (ATF6). Our findings lead to the hypothesis of an association between poor glycemic control in type 2 diabetes and increased leukocyte ROS production and chronic endoplasmic reticulum stress. This eventually promotes leukocyte-endothelial interactions, which, in turn, poses a risk of vascular complications for these patients [61].

Changes in shape or size of mitochondria have been observed in diabetic patients and animal models. Mitochondria from type 2 diabetic patients are smaller than in healthy controls [40], and hyperglycemia induce mitochondrial fragmentation in different cell types, including heart, liver, cardiovascular or pancreas [62,63]. Another example are hepatocytes from insulin resistant patients, in which mitochondria are swollen and disrupted [64].

Mitochondrial dynamics is related to ROS production under hyperglycemic conditions [63,65]. In fact, high glucose levels induce ROS production and fragmentation, and when ROS decrease mitochondria recover their activity. Yu et al. have described that, in the presence of high levels of glucose, morphological alterations of mitochondria are an upstream causal factor in ROS production, highlighting the key role of mitochondrial dynamics as a master regulator of mitochondrial activity [63]. However, the mechanisms by which mitochondrial morphology disturb ROS under hyperglycemia are not clear. Furthermore, it is important to note that abnormal glucose homeostasis may not always be a cause, but rather a consequence, of altered mitochondrial dynamics, as suggested by several studies [22,23,25].

In relationship to this, it has recently been demonstrated that livers from mfn1 knockout mice display a highly fragmented mitochondrial network. This effect was coupled with an increased mitochondrial respiration capacity and a preference for lipids as the main energy source. mfn1 knockout mice were found to be protected in a high-fat diet-induced insulin resistance model. In fact, mfn1 deficiency increased Complex I abundance and sensitized animals to the hypoglycemic effect of metformin. The authors concluded that targeting mfn1 could provide novel improvements in glucose homeostasis in insulin-resistant patients and improve the effectiveness of metformin [24].

Montagne et al. demonstrated that type 2 diabetes is associated with mitochondrial dysfunction, increased impairment of contraction and enhanced myocardial oxidative stress, regardless of body mass index [66]. Type 2 diabetes was related to mitochondrial network fragmentation in myocardium and a large decrease in mfn1 expression. In another study, Schultz et al. have confirmed that FIS1 is a key regulator in pancreatic β-cells [67]; the authors found that both glucose-stimulated insulin secretion and mitochondrial dynamics were clearly adapted to produce precise expression levels of this fission protein.

4. Targeting mitochondrial fusion and fission

The interest in the development of compounds to be directed to mitochondrial fusion, fission and mitophagy has increased exponentially in the last years [68], highlighting the importance of these targets for therapy against multiple diseases (Fig. 4). For example, mitochondrial division inhibitor-1 (mdivi-1), which can inhibit GTPase activity of DRP1 in cells, has been evaluated [69]. Furthermore, mdivi-1 can inhibit apoptosis by blocking cytochrome C release in HeLa cells [69], and can ameliorate renal injury and myocardial infarction under ischemia [70]. Another study has demonstrated that mdivi-1 can reverse the mitochondrial impairment and ROS production induced by palmitic acid by inhibiting DRP1 [71]. Mdivi-1 can also improve insulin sensitivity in conditions of insulin resistance. Some authors have demonstrated that mdivi-1 reduces mitochondrial fragmentation, oxidative stress, inflammation, atherosclerosis and improves endothelial function in diabetic mice [71,72]. In summary, the beneficial effects of mdivi-1 have been well demonstrated in short-term treatments, suggesting that this therapeutic approach could offer great benefits in the treatment of macrovascular complications in diabetic patients.

However, other studies have demonstrated that long-term treatment with this compound can inhibit mitochondrial function [73]. Treatment with mdivi-1 for more than 24-h was shown to reduce mitochondrial mass, induce apoptosis and decrease vascular cell bioenergetics and cell proliferation during myogenic differentiation [74]. Therefore, due to the inhibitory effect on cell division, mdivi-1 has the capacity to induce cell death in cancer cells [75], pointing to its potential as a therapy for cancer.

Another compound which can interfere with the GTPase activity of dynamin is dynasore, a small molecule which inhibits endocytic pathways that depend on dynamin [76]. In fact, dynasore can inhibit mitochondrial fission, as DRP1 is a dynamin-like protein. Dynasore can prevent oxidative stress and mitochondrial fission and increase cardiomyocyte survival under ischemic/reperfusion conditions [77]. It can also protect against cardiac lusitropy by maintaining mitochondrial function and morphology and levels of ATP under oxidative stress conditions, thus avoiding cell damage [77].

Taking into account the potential inhibitory effect of dynasore on dynamin-related proteins, its possible secondary effects are a matter of controversy.

Cytosolic DRP1 needs adaptors such as MFF and FIS1 to dock on mitochondria for mitochondrial fission; for this reason, it is important to develop compounds for inhibiting this interaction. P110 is a small peptide inhibitor which reduces DRP1 enzyme activity and is capable of blocking DRP1/FIS1 interactions in neurons [78], having beneficial effects for mitochondrial morphology and function. P110 has also
Mitochondrial dysfunction and its role in disease progression

**Fig. 4.** Targeting mitochondrial fusion and fission and mitophagy. The different compounds which inhibit mitochondrial fusion and can have beneficial effects by favouring mitochondrial division include mdivi-1, dynasore, P110, and S3. Other compounds with beneficial effects for mitophagy are BNIP3, rapamycin, and TXNIP. mdivi-1, mitochondrial division inhibitor-1; P110, peptide inhibitor; S3, 15-oxospiramilactone; BNIP3, BCL2/adenovirus E1B 19KDa interacting protein 3; TXNIP, thioredoxin interacting protein.

Mitochondria are highly dynamic organelles and play a very important role in maintaining homeostasis. Furthermore, they are the main source of ROS in the organism and control cellular homeostasis, cell death, and apoptosis. Therefore, their functionality is vital for life. Mitochondrial dynamics and mitochondrial biogenesis are processes which are impaired in conditions of insulin resistance in general and, in type 2 diabetes in particular. Therefore, these processes are promising pharmaceutical targets for the treatment of this group of age-related diseases.

The role of mitochondrial dynamics in energy expenditure and nutrient utilization is emerging, and mitochondrial biogenesis, dynamics, and mitophagy are related to adaptation to metabolic demands. Nutrient excess induces mitochondrial impairment and fragmentation and can inhibit autophagic flux and promote ROS production. This review has discussed how disturbances in mitochondrial dynamics contribute to the development of insulin resistance condition and type 2 diabetes. Furthermore, we have described compounds which inhibit mitochondrial fission and can have beneficial effects by favouring mitochondrial fusion, such as mdivi-1, dynasore, P110 and S3. Although the molecular mechanisms of mitochondrial dynamics and...
their relationship with diseases require clarification, the development and design of pharmacological therapies that target mitochondrial dynamics promises benefit in the treatment of cardiometabolic diseases.

Acknowledgements

The authors thank Brian Normanly (University of Valencia-CIBERehd) for his editorial assistance. This study was financed by grants P11/1424, P116/1083, P116/0301 and CIBEREd CB06/04/0071 by Carlos III Health Institute and by the European Regional Development Fund (ERDF “A way to build Europe”); UGP1-193 and UGP1-220 by FISABIO and GV/2016/169 and PROMETEO 2014/035 by the Ministry of Education of the Valencian Regional Government. V.M.V. and M.R. are recipients of contracts from the Ministry of Health of the Valencian Regional Government and Carlos III Health Institute (CES10/030 and CPII1/00637, respectively). C.B. is recipient of a Sara Borrell contract from Carlos III Health Institute (CD14/00043). S.R-L. is recipient of a Juan de la Cierva-Formación contract from the Spanish Ministry of Economy and Competitiveness (FJC1-2015–1156). O.M. de Brito, L. Scorrano, Mitofusin 2 tethers endoplasmic reticulum to mitochondria, Cell 125 (2006) 1269–1277.

The authors have nothing to disclose.

The authors thank Brian Normanly (University of Valencia-CIBERehd) for his editorial assistance. This study was financed by grants P11/1424, P116/1083, P116/0301 and CIBEREd CB06/04/0071 by Carlos III Health Institute and by the European Regional Development Fund (ERDF “A way to build Europe”); UGP1-193 and UGP1-220 by FISABIO and GV/2016/169 and PROMETEO 2014/035 by the Ministry of Education of the Valencian Regional Government. V.M.V. and M.R. are recipients of contracts from the Ministry of Health of the Valencian Regional Government and Carlos III Health Institute (CES10/030 and CPII1/00637, respectively). C.B. is recipient of a Sara Borrell contract from Carlos III Health Institute (CD14/00043). S.R-L. is recipient of a Juan de la Cierva-Formación contract from the Spanish Ministry of Economy and Competitiveness (FJC1-2015–1156). O.M. de Brito, L. Scorrano, Mitofusin 2 tethers endoplasmic reticulum to mitochondria, Cell 125 (2006) 1269–1277.

The authors have nothing to disclose.

The authors thank Brian Normanly (University of Valencia-CIBERehd) for his editorial assistance. This study was financed by grants P11/1424, P116/1083, P116/0301 and CIBEREd CB06/04/0071 by Carlos III Health Institute and by the European Regional Development Fund (ERDF “A way to build Europe”); UGP1-193 and UGP1-220 by FISABIO and GV/2016/169 and PROMETEO 2014/035 by the Ministry of Education of the Valencian Regional Government. V.M.V. and M.R. are recipients of contracts from the Ministry of Health of the Valencian Regional Government and Carlos III Health Institute (CES10/030 and CPII1/00637, respectively). C.B. is recipient of a Sara Borrell contract from Carlos III Health Institute (CD14/00043). S.R-L. is recipient of a Juan de la Cierva-Formación contract from the Spanish Ministry of Economy and Competitiveness (FJC1-2015–1156). O.M. de Brito, L. Scorrano, Mitofusin 2 tethers endoplasmic reticulum to mitochondria, Cell 125 (2006) 1269–1277.

The authors have nothing to disclose.

The authors thank Brian Normanly (University of Valencia-CIBERehd) for his editorial assistance. This study was financed by grants P11/1424, P116/1083, P116/0301 and CIBEREd CB06/04/0071 by Carlos III Health Institute and by the European Regional Development Fund (ERDF “A way to build Europe”); UGP1-193 and UGP1-220 by FISABIO and GV/2016/169 and PROMETEO 2014/035 by the Ministry of Education of the Valencian Regional Government. V.M.V. and M.R. are recipients of contracts from the Ministry of Health of the Valencian Regional Government and Carlos III Health Institute (CES10/030 and CPII1/00637, respectively). C.B. is recipient of a Sara Borrell contract from Carlos III Health Institute (CD14/00043). S.R-L. is recipient of a Juan de la Cierva-Formación contract from the Spanish Ministry of Economy and Competitiveness (FJC1-2015–1156). O.M. de Brito, L. Scorrano, Mitofusin 2 tethers endoplasmic reticulum to mitochondria, Cell 125 (2006) 1269–1277.

The authors have nothing to disclose.
Mitochondrial dynamics as a bridge between mitochondrial dysfunction and type 2 diabetes

M. Sathananthan, M. Shah, K.L. Edens, K.B. Grothe, F. Piccinini, L.P. Farrugia, H. Byrne, B. Caul, Y. Hou, S. Li, M. Wu, J. Wei, Y. Ren, C. Du, H. Wu, C. Han, H. Duan, Y. Shi, F.G. Toledo, E.V. Menshikova, V.B. Ritov, K. Azuma, Z. Radikova, J. DeLany, A.P. Arruda, B.M. Pers, G. Parlakgül, E. Güney, K. Inouye, G.S. Hotamisligil, S. Veeranki, S. Givvimani, S. Kundu, N. Metreveli, S. Pushpakumar, S.C. Tyagi, X. Cang, X. Wang, P. Liu, X. Wu, J. Yan, J. Chen, G. Wu, Y. Jin, F. Xu, J. Su, A. Zorzano, M. Liesa, M. Palacín

Six and 12 in mitochondria and relationship with glucose control in type 2 diabetes, Diabetes 56 (6) (2007) 1783–1790.

Inhibition of excessive mitochondrial fission and mitophagy causes decreased insulin secretion from β-cells, Am. J. Pathol. 183 (2013) 231–239.

Drp1-mediated mitochondrial fission and fucose in leukocytes of type 2 diabetic mice, Mol. Cell. Endocrinol. 343 (2016) 36–47.

Inhibition of Drp1 mitochondrial translocation reduced aberrant fission induced by platelet-derived growth factor, J. Cell Sci. 126 (Pt 3) (2013) 395–406.

Inhibition of excessive mitochondrial fission causes diabetic β-cell dysfunction and beta-cell death, Diabetes 65 (10) (2016) 2843–2852.

Focal adhesion kinase and Drp1-mediated mitochondrial fission contributes to mitochondrial dysfunction and neurotoxicity, J. Cell Sci. 126 (Pt 4) (2013) 1040–1049.

Inhibition of excessive mitochondrial fission provides neural protection in dopaminergic system in a Parkinson's disease model, Cell Rep. 22 (2017) 436–446.

Redox Biol. 11 (2017) 637–645

β-Cell Dysfunction in Diabetes Mellitus, Antioxid. Redox Signal. (2016). DOI: 10.1089/ars.2016.6755.

Inhibition of Drp1-mediated mitochondrial fission promotes cell proliferation in ovarian cancer cells, Biochem. Biophys. Res. Commun. 456 (1) (2015) 7–12.

Cell-permeable inhibitor of dynamin, Dev. Cell. 10 (6) (2006) 839–849.

Inhibition of excessive mitochondrial fission reduces cell death in Parkinsonian dopaminergic neurons, J. Neurochem. 139 (6) (2015) 436–446.

Inhibition of excessive mitochondrial fission mitigates dyslipidemia in high-fat diet-induced obese mice, PLoS One 12 (2017) e0178475.

Inhibition of excessive mitochondrial fission mitigates hyperglycemic conditions, PLoS One 12 (2017) e0178362.

Inhibition of excessive mitochondrial fission decreases myocardial contractile dysfunction through restoration of mitochondrial function and connexin 43 expression protein dynamin-related protein-1 in insulin-resistant skeletal muscle, J. Physiol. Regul. Integr. Comp. Physiol. 305 (8) (2013) R927–R938.

Inhibition of excessive mitochondrial fission suppresses diabetes-accelerated atherosclerosis via the inhibition of Drp1-Mediated Mitochondrial Fission, Diabetes (2016). DOI: 10.2337/db16-0195.

Inhibition of excessive mitochondrial fission provides neural protection in dopaminergic system in a Parkinson's disease model, Cell Rep. 22 (2017) 436–446.

Inhibition of excessive mitochondrial fission inhibits cell death in nerve growth factor-deprived PC12 cells, Brain Res. 1661 (2015) 43–48.

Inhibition of excessive mitochondrial fission for the treatment of neurodegenerative diseases, Adv. Exp. Med. Biol. 903 (2016) 249–258.

Inhibition of excessive mitochondrial fission preserves the structural integrity of mitochondria during apoptosis, J. Cell Sci. 128 (2015) 1421–1431.

Inhibition of excessive mitochondrial fission reduces amyloid load in a mouse model of familial Alzheimer's disease, J. Alzheimers Dis. 54 (2016) 401–413.

Inhibition of excessive mitochondrial fission reduces spongiform degeneration and improves memory in a mouse model of neurodegenerative disease, PLoS One 10 (2015) e0136982.

Inhibition of excessive mitochondrial fission reduces the severity of Huntington's disease in a fly model system, Front. Pharmacol. 8 (2017) 1017.

Mitochondrial dynamics and the role of oxidative stress in beta-cell dysfunction, J. Diabetes Complications 30 (2016) 855–863.

Inhibition of excessive mitochondrial fission reduces striatal neuron death and improves motor function in a Huntington's disease mouse model, J. Neurochem. 139 (6) (2015) 2046–2056.

Inhibition of mitochondrial fission reduces inflammation and leukocyte-endothelium interactions in leukocytes isolated from type 2 obese patients, PLoS One 8 (4) (2013) e60967.

Inhibition of excessive mitochondrial fission reduces the severity of Huntington's disease in a fly model system, Front. Pharmacol. 8 (2017) 1017.

Inhibition of excessive mitochondrial fission reduces the severity of Huntington's disease in a fly model system, Front. Pharmacol. 8 (2017) 1017.
J. Liu, X. Huang, L. Xia, L. Liu, X. Wang, H. Jin, J. Wang, Z. Song, X. Hao, Q. Chen, A small natural molecule promotes mitochondrial fusion through inhibition of the deubiquitinase USP30, Cell Res. 24 (4) (2014) 482–496. http://dx.doi.org/10.1038/cr.2014.20.

[85] R.E. Jimenez, D.A. Kuhlì, Å.B. Gustafsson, Autophagy and mitophagy in the myocardium: therapeutic potential and concerns, Br. J. Pharmacol. 171 (8) (2014) 1907–1916. http://dx.doi.org/10.1111/bph.12477.

[86] G.C. Higgins, M.T. Coughlan, Mitochondrial dysfunction and mitophagy: the beginning and end to diabetic nephropathy?, Br. J. Pharmacol. 171 (8) (2014) 1917–1942. http://dx.doi.org/10.1111/bph.12503.

[87] T. Zhang, L. Xue, L. Li, C. Tang, Z. Wan, R. Wang, J. Tan, Y. Tan, H. Han, R. Tian, T.R. Billiar, W.A. Tao, Z. Zhang, BNIP Suppresses PINK1 Proteolytic Cleavage to Promote Mitophagy, J. Biol. Chem. (2016). http://dx.doi.org/10.1074/jbc.M116.734101.

[88] B. Hartleben, M. Gödel, C. Meyer-Schwesinger, S. Liu, T. Ulrich, S. Köbler, T. Wiech, F. Grahammer, S.J. Arnold, M.T. Lindenmeyer, C.D. Cohen, H. Pavenstädt, D. Kerjaschki, N. Mizushima, G. Walz, T.B. Huber, Autophagy influences glomerular disease susceptibility and maintains podocyte homeostasis in aging mice, J. Clin. Invest. 120 (4) (2010) 1084–1096. http://dx.doi.org/10.1172/JCI39492.

[89] H. Mori, K. Inoki, K. Masutani, Y. Wakabayashi, K. Komai, R. Nakagawa, K.L. Guan, A. Yoshimura, The mTOR pathway is highly activated in diabetic nephropathy and rapamycin has a strong therapeutic potential, Biochem. Res. Commun. 384 (4) (2009) 471–475. http://dx.doi.org/10.1016/j.bbrc.2009.04.136.

[90] M. Sakaguchi, M. Isuno, K. Isshiki, T. Sugimoto, D. Koya, A. Kashihagi, Inhibition of mTOR signaling with rapamycin attenuates renal hypertrophy in the early diabetic mice, Biochem. Biophys. Res. Commun. 340 (1) (2006) 296–301. http://dx.doi.org/10.1016/j.bbrc.2005.12.012.

[91] Y. Yang, J. Wang, L. Qin, Z. Shou, J. Zhao, H. Wang, Y. Chen, J. Chen, Rapamycin prevents early steps of the development of diabetic nephropathy in rats, Am. J. Nephrol. 27 (5) (2007) 495–502. http://dx.doi.org/10.1159/000106782.

[92] C. Huang, Y. Zhang, D.J. Kelly, C.Y. Tan, A. Gill, D. Cheng, J.S. Park, C.M. Sue, C.A. Pollock, X.M. Chen, Thioredoxin interacting protein (TXNIP) regulates tubular autophagy and mitophagy in diabetic nephropathy through the mTOR signaling pathway, Sci. Rep. 6 (2016) 29196. http://dx.doi.org/10.1038/srep29196.